Nov 15, 2018 Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer's Disease Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s DiseaseBUSINESS WIRE)--Nov 15, 2018--Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for ... read morePublished on 2018-11-15